MET and neoplasm: Furthermore, the 5-year survival rate for patients with c-Met-positive tumours was significantly lower than that for patients with c-Met-negative tumours, especially in T2–4 tumours (21.0 vs 53.2%, P=0.0481, Figure 3C).